The European Medicines Agency (EMA) has been formally notified by Novartis Europharm Ltd. of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Zometa (zoledronic acid) 4 mg powder and solvent for solution for infusion and 4 mg/ 5 ml concentrate for solution for infusion. On 22 December 2009, Novartis Europharm Ltd...
More...